Breakthrough in HIV Vaccine Research: Largest-Scale Immunogenicity Comparison Reveals Promising Results

Strategic Insights -

Researchers from the Fred Hutchinson Cancer Research Center have conducted the largest-scale cross-protocol immunogenicity comparison to date, examining 13 HIV vaccine trials conducted across nine countries worldwide. The study analyzed 36 vaccine regimens, including a polyvalent DNA prime + protein boost regimen (HVTN 124) that demonstrated exceptional immunogenicity. This regimen induced high CD4+ T-cell responses and anti-V1V2 antibody responses, two key immune responses implicated in HIV vaccine protection.

Key Takeaways:

  • The study compared 13 HIV vaccine trials, including 36 vaccine regimens, conducted across nine countries worldwide.
  • The polyvalent DNA prime + protein boost regimen (HVTN 124) achieved the best anti-V1V2 antibody responses by a large margin and induced high CD4+ T-cell responses.
  • This regimen, which included Env immunogens of four subtypes, matched between prime and boost, was identified as a promising HIV vaccine design.
  • The results suggest that this vaccine design should be tested in more advanced phase clinical trials.
  • Additional HIV vaccine trials are recommended, guided by the study's findings, to improve immunogenicity and tailor vaccine development to specific subtypes.

Statistics:

  • 13 HIV vaccine trials were examined, including 36 vaccine regimens.
  • 9 countries worldwide were involved in the study.
  • The polyvalent DNA prime + protein boost regimen (HVTN 124) induced high CD4+ T-cell responses (90.5% among 13 HIV vaccine trials).
  • Anti-V1V2 antibody responses were elicited by 92.3% of participants receiving the HVTN 124 regimen.

Sources:

  • NewsRx. Studies from Fred Hutchinson Cancer Research Center in the Area of HIV/AIDS Described (A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T ...). AIDS Vaccine Week. September 22, 2025; p 17.
  • Emerging Microbes & Infections (2025;14(1):2485317) - A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.